Table 5.
Months of ERT (28 days/month) | Age (months) | Interventricular septal thickness (mm) | Left ventricular ejection fraction(%) | ||||||
---|---|---|---|---|---|---|---|---|---|
P4a | P5 | P6a | P4a | P5 | P6a | P4a | P5 | P6a | |
0.0 | 34 | 3 | 5 | 12 | 12 | 17 | 60 | 58 | 32 |
1.0 | 35 | 4 | 6 | 11 | 9 | 14 | 63 | 63 | 45 |
2.0 | 36 | 5 | 7 | – | 7 | 11 | – | – | 48 |
17.0 | – | 22 | – | – | 5 | – | – | 75 | – |
ERT enzyme replacement therapy, GSD II Glycogen storage disease type II, P patient no
apatient died after abandoning treatment; — untreated